Invest in the future of affordable fertility care

Pre‑Seed Round: USD 400,000 · 10% Equity

Pre‑money valuation $3.6M | Post‑money $4.0M

We are building the affordability layer of fertility care in APAC. Backed by HKSTP and led by a team with deep MedTech and clinical expertise.

Market Opportunity

$16B APAC market by 2033

Growing at 10.9% CAGR, with 75% unmet demand and strong demographic urgency across Southeast Asia.

Proven Technology

IVC: designed for resource‑limited settings

37 years of clinical proof. Intravaginal Culture (IVC) requires minimal lab infrastructure, scales easily, and delivers outcomes comparable to traditional IVF—making it ideal for APAC’s underserved markets.

Scalable Model

High margins, asset‑light expansion

Device sales, owned centres, and JV partnerships. Built for rapid scale across APAC.

Use of Funds

~$130k

Clinical trial

Local pilot study at Malaysian teaching hospital

~$90k

Manufacturing

Tooling & pilot batch with ISO 13485 partner

~$80k

Regulatory

MDA Class B submission & approval

~$100k

Operations & contingency

Team, runway, and buffer for 12‑18 months

Key Milestones

Already achieved

Clinical

✓ Clinical trial LOI with USIM Teaching Hospital
✓ Pilot sites ready in Malaysia & Vietnam
✓ Co-founder led first IVC birth in SE Asia

Manufacturing & IP

✓ ISO 13485 manufacturer (Freudenberg)
✓ Patent pending (Hong Kong, March 2026)
✓ FTO cleared for Malaysia; no blocking patents in APAC

Strategic

✓ MOU with IVF Academy USA (10+ years IVC practice data)
✓ Training pipeline for APAC embryologists

Regulatory

✓ MDA Class B – re‑use pathway confirmed
✓ Target approval Q4 2027 (6‑9 months)

Interested in the full investor deck?

Full deck (financials & milestones) available upon request – contact us directly.

📧 yve@myevefertility.com

📞 +852 9825 5550

Or use the form below and we’ll share the full deck under NDA.

The information on this page is provided for informational purposes only and does not constitute an offer to sell securities. Any investment decisions should be made only after reviewing full documentation and consulting with professional advisors.